AmacaThera signs exclusive global licensing agreement with Pacira BioSciences for upto US$230M

AmacaThera, a leading developer of next generation hydrogel-based drug delivery solutions that enable precise, tunable, and sustained release to improve a wide range of active therapeutics, recently announced an exclusive worldwide licensing agreement with Pacira BioSciences, Inc., a leader in non-opioid pain management, for the development and commercialization of AMT-143, an investigational long-acting non-opioid anesthetic for post-operative pain.

AmacaThera is an OBIO® member, an alumnus of all OBIO® programs, and presented at the OBIO® Investment Summit.